ReviewInternational journal of molecular sciences2020
The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Association of IgA antiphospholipid antibodies with hypercoagulability and inflammation in antiphospholipid syndrome.Journal of thrombosis and thrombolysis · 2026Observational
- From thrombosis to transplantation: The role of anti-phospholipid antibodies in liver disease management.iLIVER · 2025Review
- Article
- Ischemic stroke in anti-β2-glycoprotein I IgA-associated non-criteria antiphospholipid syndrome: a case report of arterial recanalization via antiplatelet therapy.Frontiers in immunology · 2025Article
- High Prevalence of aCL-IgA and aβ2GPI-IgA in Drug-Free Schizophrenia Patients: Evidence of a Potential Autoimmune Link.Antibodies (Basel, Switzerland) · 2024Article
- IgA Anti-β2-Glycoprotein I Antibodies as Markers of Thrombosis and Severity in COVID-19 Patients.Viruses · 2024Article
- Quantification of Antiphospholipid Antibodies: The Importance of Using an Appropriate Methodology for Each Clinical Profile.International journal of molecular sciences · 2023Article
- Anticardiolipin and anti-beta 2-glycoprotein I antibodies in patients with unexplained articular manifestations.Journal of clinical laboratory analysis · 2023Article
- Autoantibodies: are they a clue for liver diseases?Clinical and experimental hepatology · 2022Article
- COVID-19 and the antiphospholipid syndrome.Autoimmunity reviews · 2022Review
- Antiphospholipid antibodies in autoimmune thyroid diseases.Journal of clinical laboratory analysis · 2022Article
- The mosaic of autoimmunity - Finally discussing in person. The 13Autoimmunity reviews · 2022Article
- Frequency of serological markers of rheumatoid arthritis in patients with IgA anti-β2 glycoprotein I antibodies.Journal of clinical laboratory analysis · 2022Article
- Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy.International journal of molecular sciences · 2022Review
- Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.Journal of clinical medicine · 2022Review
- Neuropsychiatric Manifestations of Antiphospholipid Syndrome-A Narrative Review.Brain sciences · 2022Review
- Application Value of Combined Detection of Anti-Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome.Frontiers in immunology · 2022Observational
- Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome.Frontiers in cardiovascular medicine · 2022Review
- BushenHuoxue Recipe for the Treatment of Prethrombotic State of ACA-Positive Recurrent Miscarriage via the Regulation of the PI3K-AKT Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The specific value of IgA Anti-β2glycoprotein I antibodies (aB2GP1) in the diagnosis and management of antiphospholipid syndrome (APS) is still controversial and a matter of active debate. The relevance of the IgA aB2GP1 isotype in the pathophysiology of APS has been increasingly studied in the last years. There is well know that subjects with multiple positive APS tests are at increased risk of thrombosis and/or miscarriage. However, these antibodies are not included in the 2006 APS classification criteria. Since 2010 the task force of the Galveston International Congress on APS recommends testing IgA aB2GP1 isotype in patients with APS clinical criteria in the absence of criteria antibodies. In this review, we summarize the molecular and clinical "state of the art" of the IgA aB2GP in the context of APS. We also discuss some of the characteristics that may help to evaluate the real value of the IgA aB2GP1 determination in basic research and clinical practice. The scientific community should be aware of the importance of clarifying the role of IgA aB2GP1 in the APS diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.